Novo Nordisk stock surges 7% after Ozempic maker’s latest weight loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.
Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 products, by mimicking a hormone in the body that provides a satiated feeling and curbs hunger, but adds a different hormone in the pancreas.
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk scored a much-needed win on Friday, with early-stage data on a new weight-loss drug that suggested it could work better than the obesity blockbusters already on the market. Novo American depositary receipt was down 38% in the six months prior to Friday’s announcement,
Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying people with obesity or overweight treated with the drug achieved a 22% weight loss after 36 weeks.
Novo Nordisk shares pop 9% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
Now that we have new 'miracle' diet drugs, what's the point of exercising?
New diet drugs are making it easier to lose weight. So does that mean we can stop exercising? Health experts say no. There is ...
E!22h
Oprah Winfrey Shares What She Learned About “Thin People” After Experience With Weight-Loss Drug
Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...
Hoodline3d
Harvard Experts Advocate Exercise Over Diet Drugs for Full-Spectrum Health
Harvard experts highlight the broad health benefits of exercise beyond weight loss, even with new diet drugs available.
Medscape11d
New Weight Loss Drugs May Fight Obesity-Related Cancer, Too
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
Popular weight loss drugs could be cheaper for some Americans: What you need to know
If successful, the result could be lower Medicare Part D prices for drugs used to create a variety of conditions, such as ...
NOLA.com10d
Can weight loss drugs curb alcohol addictions? New research looks at the possibility.
Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.
Benefits Pro2d
Challenges employers will face in 2025 with weight-loss drugs
The weight loss market is evolving at an unprecedented rate with the advancements in anti-obesity medications, and 2025 will ...